These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24308894)

  • 1. Predictive value of prospective memory for remission in first-episode schizophrenia.
    Zhou FC; Xiang YT; Wang CY; Dickerson F; Kreyenbuhl J; Ungvari GS; Au RW; Zhou JJ; Zhou Y; Shum D; Man D; Lai KY; Tang WK; Yu X; Chiu HF
    Perspect Psychiatr Care; 2014 Apr; 50(2):102-10. PubMed ID: 24308894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
    Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
    J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
    Trampush JW; Lencz T; DeRosse P; John M; Gallego JA; Petrides G; Hassoun Y; Zhang JP; Addington J; Kellner CH; Tohen M; Burdick KE; Goldberg TE; Kane JM; Robinson DG; Malhotra AK
    Schizophr Bull; 2015 Nov; 41(6):1237-47. PubMed ID: 26409223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.
    Agid O; Schulze L; Arenovich T; Sajeev G; McDonald K; Foussias G; Fervaha G; Remington G
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1017-22. PubMed ID: 23706529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.
    Pawelczyk T; Pawelczyk A; Rabe-Jablonska J
    J Psychiatr Pract; 2014 Jul; 20(4):301-7. PubMed ID: 25036587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
    Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
    J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
    Yoshimura R; Ueda N; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):256-61. PubMed ID: 20218790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Chinese First-Episode Schizophrenia Trial: background and study design.
    Han X; Yuan YB; Yu X; Zhao JP; Wang CY; Lu Z; Yang FD; Dong H; Wu YF; Ungvari GS; Xiang YT; Chiu HF
    East Asian Arch Psychiatry; 2014 Dec; 24(4):169-73. PubMed ID: 25482837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
    Jakubovski E; Carlson JP; Bloch MH
    J Clin Psychiatry; 2015 Nov; 76(11):1535-45. PubMed ID: 26581028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.
    Ratajczak P; Kus K; Jarmuszkiewicz Z; Woźniak A; Cichocki M; Nowakowska E
    Pharmacol Rep; 2013; 65(1):30-43. PubMed ID: 23563021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.
    Wang CH; Li Y; Yang J; Su LY; Geng YG; Li H; Wang JK; Mu JL
    Schizophr Res; 2013 Mar; 144(1-3):129-35. PubMed ID: 23352776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
    Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
    Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study.
    Liu CC; Chien YL; Hsieh MH; Hwang TJ; Hwu HG; Liu CM
    J Clin Psychopharmacol; 2013 Feb; 33(1):18-23. PubMed ID: 23277261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
    Díaz I; Pelayo-Terán JM; Pérez-Iglesias R; Mata I; Tabarés-Seisdedos R; Suárez-Pinilla P; Vázquez-Barquero JL; Crespo-Facorro B
    Psychiatry Res; 2013 Apr; 206(2-3):181-7. PubMed ID: 23159063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.